118 related articles for article (PubMed ID: 3122702)
1. Factor VIII assays. Assessment of variables.
Brandt JT; Triplett DA; Musgrave K; Arkin C; Bovill EG; Lucas FV; Rock WA
Arch Pathol Lab Med; 1988 Jan; 112(1):7-12. PubMed ID: 3122702
[TBL] [Abstract][Full Text] [Related]
2. Factor VIII (antihemophilic factor) assay results in the 1976 College of American Pathologists Survey Program.
Harms CS; Triplett DA; Koepke JA
Am J Clin Pathol; 1978 Sep; 70(3 Suppl):560-2. PubMed ID: 707422
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting the performance of factor VIII coagulant activity assays. Results of proficiency surveys of the College of American Pathologists.
Arkin CF; Bovill EG; Brandt JT; Rock WA; Triplett DA
Arch Pathol Lab Med; 1992 Sep; 116(9):908-15. PubMed ID: 1524453
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program.
Brandt JT; Arkin CF; Bovill EG; Rock WA; Triplett DA
Arch Pathol Lab Med; 1990 Feb; 114(2):135-41. PubMed ID: 2405809
[TBL] [Abstract][Full Text] [Related]
5. Performance characteristics of fibrinogen assays. Results of the College of American Pathologists Proficiency Testing Program 1988-1991.
Bovill EG; McDonagh J; Triplett DA; Arkin CF; Brandt JT; Hayes TE; Kaczmarek E; Long T; Rock WA
Arch Pathol Lab Med; 1993 Jan; 117(1):58-66. PubMed ID: 8418764
[TBL] [Abstract][Full Text] [Related]
6. Comparison of six commercial plasma references for factor VIII, factor IX and von Willebrand factor. On behalf of the Subcommittee for Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.
Kasper CK; Aronson DL; Davignon G; Foster P; Hillman-Wiseman C; Lusher JM; Manco-Johnson M; Meade JB; Montgomery RR; Rickles FR
Thromb Haemost; 1995 Sep; 74(3):987-9. PubMed ID: 8571334
[TBL] [Abstract][Full Text] [Related]
7. Standardization of Factor VIII-III. Establishment of a stable reference plasma for Factor VIII-related activities.
Barrowcliffe TW; Tydeman MS; Kirkwood TB; Thomas DP
Thromb Haemost; 1983 Oct; 50(3):690-6. PubMed ID: 6417818
[TBL] [Abstract][Full Text] [Related]
8. Cap survey results for factor VIII assays (1977-1978).
Kocoshis TA; Triplett DA
Am J Clin Pathol; 1979 Aug; 72(2 Suppl):346-51. PubMed ID: 474513
[TBL] [Abstract][Full Text] [Related]
9. Measurement of factor VIII. A potential risk factor for vascular disease.
Brandt JT
Arch Pathol Lab Med; 1993 Jan; 117(1):48-51. PubMed ID: 8418762
[TBL] [Abstract][Full Text] [Related]
10. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
11. Factor assay (VIII and IX) results in the College of American Pathologists Survey Program (1980-1982).
Christensen RL; Triplett DA
Am J Clin Pathol; 1983 Oct; 80(4 Suppl):633-42. PubMed ID: 6414289
[TBL] [Abstract][Full Text] [Related]
12. Standardization of Factor VIII-IV. Establishment of the 3rd International Standard for Factor VIII: C concentrate.
Barrowcliffe TW; Curtis AD; Thomas DP
Thromb Haemost; 1983 Oct; 50(3):697-702. PubMed ID: 6417819
[TBL] [Abstract][Full Text] [Related]
13. Standards for assay of von Willebrand factor concentrates: a collaborative study.
Fricke WA; Lamb MA; Rastogi SC
Thromb Haemost; 1993 Aug; 70(2):351-6. PubMed ID: 8236147
[TBL] [Abstract][Full Text] [Related]
14. International biological standards for coagulation factors and inhibitors.
Hubbard AR
Semin Thromb Hemost; 2007 Apr; 33(3):283-9. PubMed ID: 17427063
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of a chromogenic substrate method for determination of factor VIII activity.
Rosén S; Andersson M; Blombäck M; Hägglund U; Larrieu MJ; Wolf M; Boyer C; Rothschild C; Nilsson IM; Sjörin E
Thromb Haemost; 1985 Dec; 54(4):818-23. PubMed ID: 3937277
[TBL] [Abstract][Full Text] [Related]
16. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
[TBL] [Abstract][Full Text] [Related]
17. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
Lundblad RL; Kingdon HS; Mann KG; White GC
Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
[TBL] [Abstract][Full Text] [Related]
18. Collaborative study on assays of activated FIX (FIXa). On behalf of the factor VIII and factor IX subcommittee of the ISTH. International Society on Thrombosis and Haemostasis.
Gray E; Walker D; Heath A; Barrowcliffe TW
Thromb Haemost; 1996 Dec; 76(6):1114-7. PubMed ID: 8972040
[TBL] [Abstract][Full Text] [Related]
19. A collaborative study to establish a Korean Standard for factor VIII:C concentrate.
Kang HN; Kim SN; Lee SH; Hong SH
Thromb Res; 2004; 113(3-4):261-7. PubMed ID: 15140591
[TBL] [Abstract][Full Text] [Related]
20. Quality assurance in hemostasis: the perspective from the College of American Pathologists proficiency testing program.
Cunningham MT; Brandt JT; Chandler WL; Eby CS; Hayes TE; Krishnan J; Lefkowitz JB; Olson JD; Stasik CJ; Teruya J; Van Cott EM
Semin Thromb Hemost; 2007 Apr; 33(3):250-8. PubMed ID: 17427059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
